TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24486592
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 10% w/w freeze-dried black raspberry gel (BRB), 0.5 g × q.i.d., for 12 weeks
Study: 24486592
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (identical formulation devoid of BRB)
Study: 22395584
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2% and tretinoin 0.025% combination gel
Study: 20071811
Drug: Lignocaine with
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine with adrenaline + 4 mg Dexamethasone (Group C)
Study: 16871922
Drug: Benzalkonium chloride
Normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzalkonium chloride (BKC) 0.01% in saline nasal spray
Study: 11706096
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (150 mg daily for 1 week, then 300 mg daily for 5 weeks)
Study: 9282701
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (prescription and verbal instructions)
Study: 9282701
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (prescription, syringe, and demonstration)
Study: 9282701
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (prescription, syringe with marked line, and demonstration)
Study: 7942479
Drug: Amiodarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone treatment for 3 to 6 months (n = 11)
Study: 7942479
Drug: Amiodarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone treatment for > 1 year (n = 13)
Study: 23547078
Drug: Rituximab purging
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab purging (P+; 375 mg/m(2) once per week for 4 weeks)
Study: 23547078
Drug: Maintenance rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance rituximab (M+; 375 mg/m(2) once every 2 months for four infusions)
Study: 18171718
Drug: Community based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community based occupational therapy (10 sessions over five weeks)
Study: 18171718
Drug: Community based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community based occupational therapy
Study: 17148797
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia followed by postoperative intravenous patient‐controlled analgesia with morphine
Study: 17148797
Drug: Combined spinal‐epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal‐epidural anaesthesia followed by postoperative epidural infusion of bupivacaine 0.1% with fentanyl 2 microg/mL
Study: 8785144
Drug: Tramadol 200
Normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 200 mg i.v.
Study: 8785144
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg i.v.
Study: 1488688
Drug: Mefloquine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (4 tablets, 1000 mg) plus tetracycline (250 mg qid for 7 days)
Study: 1488688
Drug: MSP (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP (4 tablets, one tablet contains 250 mg mefloquine, 500 mg sulfadoxine and 25 mg pyrimethamine) plus tetracycline (250 mg qid for 7 days)
Study: 3698068
Drug: 750-ml spacer
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750-ml spacer
Study: 23932140
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin sulfate 10,000 IU
Study: 23932140
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin sulfate 5,000 IU
Study: 18332450
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron sucrose (200 mg iron) once per week for 4 weeks then once every other week for a further 4 weeks
Study: 18332450
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous succinate, 200 mg three times per day for 8 weeks
Study: 12602671
Drug: Pari Inhalierboy
Normalized name: Paris quadrifolia extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pari Inhalierboy (2 mg budesonide)
Study: 12602671
Drug: Pari LC
Normalized name: Pari LC Pediatric Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pari LC Jet Plus (2 mg budesonide)
Study: 12602671
Drug: Maxin MA-2
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxin MA-2 (2 mg budesonide)
Study: 12602671
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg budesonide orally
Study: 12602671
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg budesonide intravenously
Study: 10584978
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid 500 mg/day for 28 days (group B)
Study: 10584978
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid 500 mg/day for 14 days (group A)
Study: 8947990
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention in managing warfarin therapy
Study: 1835223
Drug: Intramuscular teicoplanin
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular teicoplanin
Study: 24732048
Drug: Choice to
Normalized name: TOLNAFTATE 1 g in 100 g TOPICAL CREAM [Quality Choice Tolnaftate Antifungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice to have standard treatment or take part in the trial (choice)
Study: 17889679
Drug: One-visit treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit treatment
Study: 17889679
Drug: Two-visit treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit treatment
Study: 17889679
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between one-visit and two-visit treatments
Study: 12218286
Drug: Dithranol ointment
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol ointment (2%) once daily for 30 min + vehicle of calcipotriol (50 microg/g) twice daily
Study: 12218286
Drug: Dithranol ointment
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dithranol ointment (2%) once daily for 30 min + calcipotriol (50 microg/g) twice daily
Study: 8641492
Drug: Daily hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hMG beginning on cycle day 3 (Group A)
Study: 8641492
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CC days 3 through 7 followed by hMG from day 7 onward (Group B)
Study: 1295525
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone 0.1% (Maxidex)
Study: 1295525
Drug: Topical fluorometholone
Normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical fluorometholone 0.1% (FML Liquifilm)
Study: 1295525
Drug: Topical naphazoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical naphazoline hydrochloride 0.1% (Albalon)
Study: 1295525
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (FML and Albalon)
Study: 6470194
Drug: Thioridazine tablets
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine tablets
Study: 6470194
Drug: Thioridazine suspension
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine suspension
Study: 6470194
Drug: Thioridazine tablets
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine tablets and suspension (comparison)
Study: 22525206
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg once per day)
Study: 20581787
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg/day for 8 weeks
Study: 22588361
Drug: DHEA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (100 mg/day)
Study: 14530158
Drug: Altered fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altered fractionation schemes based on different radiobiological mechanisms; specific dosage and duration not available.
Study: 10487657
Drug: HRT (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (transdermal 17beta‐estradiol, 50 microg/day; plus oral norethisterone acetate, 1 mg/day)
Study: 10487657
Drug: MFP (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP (oral monofluorophosphate, 20 mg/day)
Study: 8765440
Drug: 7-day continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day continuous etoposide infusion at doses from 30 to 75 mg/m2 per day (schedule A)
Study: 8765440
Drug: 21-day continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-day continuous etoposide infusion at doses from 18 to 40 mg/m2 per day (schedule B)
Study: 1531552
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment by the general practitioner
Study: 23032981
Drug: Active TENS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TENS treatment
Study: 29429636
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg/day
Study: 22336235
Drug: Paclitaxel liposome
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel liposome (135 mg/m²)
Study: 22336235
Drug: Paclitaxel liposome
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel liposome plus oxaliplatin (135 mg/m² + 125 mg/m²)
Study: 21030905
Drug: Everolimus with
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus with reduced calcineurin inhibitor exposure
Study: 17823041
Drug: Outpatient oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient oral hydration and N‐acetylcysteine
Study: 17823041
Drug: Inpatient intravenous
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient intravenous hydration alone (standard therapy)
Study: 11809337
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg progesterone/g cream
Study: 11809337
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg progesterone/g cream
Study: 10416252
Drug: 1% sodium
Normalized name: Dextrose 5% and 0.11% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sodium fluorescein solution applied with Pulmicort Topinasal (budesonide) metered pump bottles
Study: 2842144
Drug: Flumazenil (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1.0 mg)
Study: 7590022
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of flumazenil (0.25 mg/h)
Study: 7590022
Drug: Open study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open study with flumazenil (1.0 mg)
Study: 28647339
Drug: Amoxicillin (1500mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1500mg/day for 7 days)
Study: 26521100
Drug: Prasugrel (loading/maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (loading/maintenance dose: 20/3.75mg)
Study: 11367898
Drug: Adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant systemic treatment
Study: 9028057
Drug: Naltrexone (NAL)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NAL) at doses of 0.5, 1.0 and 1.5 mg/kg every 48 hours
Study: 1506125
Drug: imidazole 2-hydroxybenzoate
Normalized name: imidazole-2-hydroxybenzoate
DrugBank: Imidazole salicylate (DB13860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: imidazole 2-hydroxybenzoate (750 mg, t.i.d., for three days)
Study: 6360263
Drug: Regimen RSHZ
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen RSHZ (rifampicin, streptomycin, isoniazid, pyrazinamide) daily for 3 months
Study: 6360263
Drug: Regimen RSHZ/SHZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen RSHZ/SHZ (rifampicin discontinued after 3 months, remaining drugs given twice weekly for 2 months)
Study: 6360263
Drug: Basic 3-month
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Basic 3-month regimen followed by unsupervised maintenance therapy with isoniazid for a further 3 months
Study: 6360263
Drug: Intermittent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent administration of rifampicin
Study: 25226843
Drug: Doxorubicin-eluting bead-transarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-eluting bead-transarterial chemoembolization (DEB TACE) combined with systemic sorafenib (400 mg twice a day)
Study: 9622285
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (ethyl esters) 2 g/day
Study: 2970456
Drug: Sertraline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 400 mg
Study: 25986018
Drug: High-dose DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DHA (0.86%) and AA (0.91%) supplementation
Study: 25986018
Drug: High-dose DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DHA and AA supplementation
Study: 23601026
Drug: Levofloxacin-containing sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-containing sequential therapy (LCS)
Study: 23601026
Drug: Levofloxacin-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-containing quadruple therapy (LCQ)
Study: 20498324
Drug: PA-824 200
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA-824 200 mg daily
Study: 20498324
Drug: PA-824 600
Normalized name: OMS-824
DrugBank: OMS-824 (DB17874)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-824 600 mg daily
Study: 20498324
Drug: PA-824 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-824 1,000 mg daily
Study: 20498324
Drug: PA-824 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-824 1,200 mg daily
Study: 20498324
Drug: Standard antituberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antituberculosis treatment
Study: 8227460
Drug: Didanosine (DDI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (DDI) 375 mg twice daily for 4 days
Study: 8227460
Drug: Didanosine (DDI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (DDI) 375 mg twice daily for 4 days with Ketoconazole (KET) 200 mg daily for 4 days
Study: 8227460
Drug: Ketoconazole (KET)
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole (KET) 200 mg daily for 4 days
Study: 2979066
Drug: Anesthetic doses
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetic doses of fentanyl (46 +/- 1.3 micrograms/kg) and oxygen (group I)
Study: 2979066
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of fentanyl (3 to 4.7 micrograms/kg; mean = 3.54 +/- 0.1 micrograms/kg) + etomidate (0.4 mg/kg) intravenously (IV) (group II)
Study: 29697768
Drug: NDV-3A vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDV-3A vaccine (1 intramuscular dose)
Study: 26832428
Drug: Topical 90%
Normalized name: phenol topical 90% compounding liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 90% medical‐grade kanuka honey and 10% glycerine applied twice daily for 12 weeks after washing with antibacterial soap.
Study: 26832428
Drug: Antibacterial soap
Normalized name: QSR Antibacterial Soap Product
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibacterial soap (Protex, triclocarban‐based) applied twice daily for 12 weeks.
Study: 25070094
Drug: Artesun‐Plus (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesun‐Plus (fixed-dose combination of artesunate and amodiaquine)
Study: 12475453
Drug: Intravenous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxaparin (0.5 mg/kg)
Study: 12475453
Drug: Intravenous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoxaparin (0.5 mg/kg) with eptifibatide
Study: 7795721
Drug: Minoxidil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil (1 ml, 2% solution)
Study: 7795721
Drug: Nitroglycerine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine (2.5 g, 10% ointment)
Study: 798582
Drug: Clozapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (300 mg per day)
Study: 25957224
Drug: Clopidogrel-aspirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin therapy
Study: 29112701
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment for <6 cycles
Study: 29112701
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment for 6 cycles
Study: 29112701
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment for >6 cycles
Study: 23467946
Drug: HTS 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTS 5% bolus (125 cc every 6 hrs, N: 11)
Study: 23467946
Drug: HTS 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTS 5% infusion (500 cc for 24 hrs, N: 12)
Study: 23467946
Drug: Mannitol 20%
Normalized name: mannitol 20% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 20% (1 g/kg bolus, repeated 0.25‐0.5 g/kg every 6 hrs for 3 days, N: 10)
Study: 2407911
Drug: Non-treatment for
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment for alcohol abuse
Study: 26780348
Drug: Δ9-THC (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ9-THC (all doses)
Study: 10942184
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline at 1000 hours
Study: 10942184
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline at 2200 hours
Study: 10942184
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg pentoxifylline (both treatments)
Study: 16988209
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg)
Study: 1616168
Drug: Ranitidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (100 mg)
Study: 3895761
Drug: Bepridil 200
Normalized name: bepridil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil 200 mg/day
Study: 6362386
Drug: Bepridil 300
Normalized name: bepridil 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil 300 mg/day
Study: 3895761
Drug: Bepridil 400
Normalized name: bepridil 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil 400 mg/day
Study: 20345546
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 50 microg once daily into each nostril for 3 months
Study: 20345546
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray once daily into each nostril for 3 months
Study: 15877290
Drug: High-dose growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose growth hormone (GH) administration for 4 hours
Study: 15877290
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GH administration)
Study: 12544508
Drug: Irbesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (angiotensin II type 1 receptor blocker)
Study: 12544508
Drug: Atenolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (beta 1-adrenergic receptor blocker)
Study: 11827617
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and behavioral treatment including education about memory loss, relaxation training, memory skills training, and cognitive restructuring for memory-related beliefs.
Study: 8526782
Drug: Nifedipine oros
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine oros 30 mg/day
Study: 8526782
Drug: Nifedipine oros
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine oros 60 mg/day (for non-responders)
Study: 2191779
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine (0.2 mg daily)
Study: 2191779
Drug: Oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral captopril (122.9 mg daily)
Study: 2191779
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine and Oral captopril
Study: 31170680
Drug: Hépar (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hépar (1 L daily for 14 days)
Study: 31170680
Drug: Low-mineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-mineral water (1 L daily for 14 days)